Dermatology CE Activities

LATEST Dermatology ARTICLES

RSS feed: Dermatology Articles Dermatology Articles
  • Interferon-γ Underlying Thymoma-Associated Immune Dysregulation November 12, 2026
    In an observational study, thymoma-associated immune dysregulation was characterized by interferon-γ pathway activation. Four patients with severe disease treated with Janus kinase 1/2 inhibitors had clinical and biomarker responses.
    Iivo Hetemäki, Chen Wang, Rachel Wu, Joseph Pechacek, Taura Webb, Deanna Riley, Lucas dos Santos Dias, Heather Moorman, Princess Barber, Lindsey B. Rosen, Annalie Harris, Sebastian Ochoa, Karthik Darma, Maria Semenova, Laercio Lopez Da Silva, Kai Kisand, Tovah E. Markowitz, Peter D. Burbelo, Monika Fischer, Mark Raffeld, Tyler Hulett, Jennifer Stoddard, Sergio D. Rosenzweig, Christopher G. Kanakry, Kathy L. McGraw, Joseph Rocco, Luigi D. Notarangelo, Christa S. Zerbe, Ivan Fuss, Anjali Rai, Theo Heller, Patrick J. Loehrer, Eliisa Kekäläinen, Alexandra F. Freeman, Arun Rajan, Timi Martelius, Katherine R. Calvo, Steven M. Holland, Roderick Marion, Stefania Pittaluga, Michail S. Lionakis
  • Cancer Vaccines — From Treatment to Prevention November 11, 2026
    Vaccines have been among the most transformative advances in modern medicine, dramatically reducing the global burden of infectious diseases. Vaccines against the hepatitis B virus (HBV) and human papillomavirus (HPV) also play an important role in reducing the incidence of certain virus-associated cancers. However, until now, efforts to develop vaccines...
    Mark Yarchoan
  • Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma November 11, 2026
    In a trial of the individualized neoantigen therapy intismeran in patients with resected stage IIB to IV melanoma, 24-month recurrence-free survival was 82.2% with intismeran–pembrolizumab and 70.0% with pembrolizumab alone.
    Georgina V. Long, Muhammad A. Khattak, Helen J. Gogas, Dirk Schadendorf, Ana Arance, Matteo S. Carlino, Piotr Rutkowski, Gareth Rivalland, Antoni Ribas, Janice M. Mehnert, Patrick A. Ott, Reinhard Dummer, Paola Queirolo, Christoffer Gebhardt, Caroline Dutriaux, Carlos Rojas, Yuanbin Chen, Lisa M. Tachiki, Ronnie Shapira-Frommer, Oliver Bechter, Ryan J. Sullivan, Alexander M.M. Eggermont, Laureen S. Ojalvo, Michelle Brown, Jinchun Zhang, Dmitri O. Grebennik, Mizuho Fukunaga-Kalabis, Paolo A. Ascierto, Michele Del Vecchio, the INTerpath-001 Investigators*

RMEI LIGHTNING TALKS

View Details

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.
View Details

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.

Previously Published CE Activities